← boardnext 2027-05
BOLT
Bolt Biotherapeutics, Inc.distress 5/10 · elevated risk$4.09+2%today-42% from 52w high
Oncology 1
Lead: Gastric Cancer Adenocarcinoma Metastatic · target PD-1
Revenue
pre-revenue
Liquidity
$24M
Runway
0.7 yrs
Shares 1y
+0%
Price & events
-34.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.7%
1D
-2.9%
1W
+2.0%
1M
-24.1%
3M
-34.6%
6M
-31.3%
1Y
-72.0%
2Y
-98.4%
5Y
-99.4%
All
Overview
- Market Cap
- $7.86M
- Volume
- 4.10K
- 52 Week Range
- $3.78 – $7.09
- Total Shares
- 1.92M
- Float Shares
- 1.77M
- Short %
- 0.87%
- % Held by Insiders
- 3.47%
- % Held by Institutions
- 28.86%
- RVOL
- 0.15x
- Beta
- 1.17
Pipeline stages · 1 programs
BDC-4182
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-05 Estimated 50% readout ~2027-06-15 | Phase 1/2 | BDC-4182 | Gastric Cancer Adenocarcinoma Metastatic, Gastroesophageal Adenocarcinoma | — | recruiting |
| 2025-08-01 | Phase 1 | BDC-3042, Cemiplimab | Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Head and Neck Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, Melanoma | 17 | terminated |
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 1
- third quarter of 2026Guided 70%readoutPhase 1BDC-4182 · Initial clinical data readout from Phase 1 dose escalation studySEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 1,921,567 · 0 offerings/1y · 0 PIPEs
- 2024-11-14SC 13G/Astrategic_stake
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-05-29Rodman & RenshawBuy
- 2026-05-28HC Wainwright & Co.Buy
- 2026-03-13HC Wainwright & Co.Buy
- 2025-08-15Lake StreetBuy
- 2025-05-20Lake StreetBuy
- 2025-05-13StifelHold
Competitors — PD-1
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- NCNANuCana plc$28.3B · D2
- EXELEXELIXIS, INC.$13.8B · D0
- IOVAIOVANCE BIOTHERAPEUTICS, INC.$2.3B · D4
- CGEMCullinan Therapeutics, Inc.$1.1B · D1
- REPLReplimune Group, Inc.$906M · D2
- ALXOALX ONCOLOGY HOLDINGS INC$262M · D5
- BCABBioAtla, Inc.$107M · D8
- IOBTQIO Biotech, Inc.$71,949 · D5
Recent news
- 2026-07-05Bolt Biotherapeutics Inc (BOLT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
- 2026-06-30BOLT Q1 2026 Earnings: Wider-than-Expected Loss Highlights Development Costs - Guidance Downgrade Alert - dars.gov.et
- 2026-06-26BOLT Forecast — Price Target — Prediction for 2027 - TradingView
- 2026-06-25Bolt Biotherapeutics, Inc. Actuals & Estimates (MUN:6LP0) - TradingView
- 2026-06-25Price to book forward of Bolt Biotherapeutics, Inc. – NASDAQ:BOLT - TradingView
- 2026-06-21Bolt Biotherapeutics (BOLT) Slides 5% in Heavy Trading as Key Support Level Approaches - Liquidity Order Flow - dars.gov.et
- 2026-06-18Bolt Biotherapeutics Inc (BOLT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
- 2026-06-18Bolt Biotherapeutics Inc (BOLT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.